HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioid-Withdrawal Beverage Seller Latest Target Of FDA-FTC Joint Enforcement

This article was originally published in The Rose Sheet

Executive Summary

While essentially all products labeled as dietary supplements but marketed with claims to treat diseases or illnesses could be targets of FTC enforcement against unsubstantiated advertising, FDA warnings to firms linked to those products generally don't discuss violations of FTC rules. But the warning to Up-Inya Beverages, like firms previously identified as making opioid-withdrawal claims, included an explanation of how it's in FTC's crosshairs, too.


Related Content

Opioid Drug Sales Online Draw US FDA Warnings, Prompt Summit Meeting
Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts